Meningitis Clinical Trial
Official title:
Encephalitis Sentinel Surveillance in Intensive Care Units in Brazil
Verified date | May 2022 |
Source | D'Or Institute for Research and Education |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Our proposal is to develop a sentinel syndromic surveillance strategy to identify encephalitis cases possibly related to emerging pathogens admitted to ICUs in Brazil. "Sentinel" to allow a diagnostic intensive approach on a smaller number of cases, "syndromic" to guarantee a sensitive criterion to include new or unexpected pathogens, and in ICUs to prioritize potentially severe threats. In a resource-limited setting it won't be possible to monitor and investigate all cases of encephalitis, so a cost-effective algorithm for early identification of the cases that are most likely to be caused by unusual, unexpected or emerging pathogens must be developed. As universal surveillance of encephalitis is not recommended in Brazil, data on incidence, causes and prognosis is not available, leaving a gap in the understanding of the epidemiology of this central nervous system disease in the country. This study will review cases of encephalitis admitted in the last five years to ICUs in a large metropolitan area. Its results will help understand the epidemiology of encephalitis in Brazil and will provide data to build a strategy for early identification of outbreaks and of emerging infectious diseases.
Status | Completed |
Enrollment | 451 |
Est. completion date | January 1, 2022 |
Est. primary completion date | June 1, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Month and older |
Eligibility | Inclusion Criteria: Identification of suspected case of central nervous system infections in the Epimed Database of non-surgical and non-neonatal ICU admissions: risk greater or equal to 10% - sensitivity of 88.69%, a specificity of 85.57%, area under the Receiver Operating Characteristics (ROC) curve of 0.892 (95% confidence interval 0.864 - 0.921, P<0.0001) - by a diagnostic prediction tool for central nervous system infection (CNSI) developed by the authors for this study. Suspected cases had their medical records reviewed. Those who fulfilled the diagnostic criteria of CNSI as follows were included as a case: Brain abscess or suppurative intracranial infections: diagnosis of brain abscess requires at least one of the following criteria: - Organism identified from brain tissue - Abscess on gross anatomic or histopathologic exam - Two of the following: headache, dizziness, fever, localizing neurological signs, changing level of consciousness or confusion; and one of the following: organism on microscopic examination of brain or abscess tissue, neuroimaging evidence of infection, or diagnostic serology. -Encephalitis: Involvement of the brain parenchyma by the infectious agent. Diagnosis of encephalitis by Venkatesan et al19 requires: - Major criteria: Presence of decreased or altered level of consciousness, lethargy or personality change lasting at least 24 hours and exclusion of encephalopathy due to other non-infectious aetiologies - Two of the following for possible encephalitis, three of the following for probable or confirmed encephalitis: fever, seizures, new onset focal neurological findings, cerebrospinal fluid (CSF) white blood cell (WBC) count >10x106/L, abnormal neuroimaging and electroencephalography. -Meningitis: Patients without criteria for encephalitis, and at least one of the following criteria: - Organism identified from CSF - The presence of two of the following: fever or headache, meningeal signs or cranial nerve signs (and hypothermia, apnoea, bradycardia or irritability for those under <1 year of age); and one of the following: increased WBC count (=5 cells/mm3), increased protein and/or decreased glucose in CSF, an organism on Gram stain or culture, or diagnostic serology. Exclusion Criteria: Participants without CNSI case definition, readmissions during the period of data collection (only the first admission was evaluated), evidence of nosocomial or postoperative neuroinfection, diseases of inflammatory or autoimmune etiology, missing important data for analysis or diagnosis. |
Country | Name | City | State |
---|---|---|---|
Brazil | Instituto Nacional de Infectologia | Rio de Janeiro | RJ |
Lead Sponsor | Collaborator |
---|---|
D'Or Institute for Research and Education | Centers for Disease Control and Prevention, Oswaldo Cruz Foundation |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | In-hospital mortality | January 2012 to December 2019 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03445416 -
Increasing Healthcare Engagement Via Routine Vaccination Among Young Black Men Who Have Sex With Men
|
N/A | |
Completed |
NCT02526394 -
Pertussis and Meningitis C Concomitant Vaccination in Adolescents
|
Phase 4 | |
Completed |
NCT01442675 -
Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine
|
Phase 2 | |
Completed |
NCT00539032 -
Immunology and Safety of Menactra® in Children in Saudi Arabia
|
Phase 3 | |
Terminated |
NCT00428051 -
Colombia Epidemiologic Surveillance Study
|
N/A | |
Recruiting |
NCT05496673 -
Meningitis: Burden, Causes, Screening and Prevention in Rural Northern Uganda
|
N/A | |
Completed |
NCT02003495 -
Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine
|
Phase 3 | |
Recruiting |
NCT00901602 -
Lebanese Interhospital Pneumococcal Surveillance Program
|
||
Completed |
NCT00850603 -
Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®
|
Phase 4 | |
Completed |
NCT02591290 -
Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects
|
Phase 4 | |
Completed |
NCT03112031 -
Treatment With Tamoxifen in Cryptococcal Meningitis
|
Phase 2 | |
Completed |
NCT02881957 -
Hypovitaminosis D in Neurocritical Patients
|
Phase 2/Phase 3 | |
Completed |
NCT06334796 -
Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology
|
Early Phase 1 | |
Completed |
NCT03378258 -
Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA.
|
||
Recruiting |
NCT05637645 -
Different Approaches of Spinal Anesthesia in Patients Undergoing Cesarean Section
|
N/A | |
Completed |
NCT02841254 -
Diagnostic Performance of Clinical Signs Patients Suspected of Meningitis to Emergencies
|
N/A | |
Completed |
NCT02003313 -
Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine
|
Phase 3 | |
Recruiting |
NCT01619462 -
Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children
|
Phase 3 | |
Completed |
NCT01239043 -
Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination
|
Phase 2 | |
Completed |
NCT00495690 -
Impact of Daily Zinc Supplementation to Infants Born With Low Birth Weight on Death and Severe Disease
|
Phase 3 |